Organon (1OGN) Stock Price & Analysis
1OGN Stock Chart & Stats
- Day’s Range
- EUR 12.32 - EUR 12.42
- 52-Week Range
- EUR 4.86 - EUR 17.00
- Previous Close
- EUR 12.36
- Volume
- 0
- Average Volume (3M)
- 9
- Market Cap
- EUR 3.24B
- Enterprise Value
- EUR 11.08B
- Total Cash (Recent Filing)
- EUR 1.46B
- Total Debt (Recent Filing)
- EUR 8.55B
- Price to Earnings (P/E)
- 17.5
- Beta
- 0.31
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.56%
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare Portfolio
The combination of women’s health, established medicines, and biosimilars gives Organon multiple product categories and geographic revenue channels. This diversification can reduce reliance on any single therapy, support recurring demand from mature products, and provide a broader platform for commercial partnerships.
MIUDELLA Regulatory Opportunity
MIUDELLA adds a potential hormone-free contraceptive option to Organon’s women’s health portfolio, with six-year study results and an active FDA review. If approved, the product could broaden the franchise and create a longer-duration commercial opportunity, although approval remains pending.
Solid Underlying Operating Margins
Despite weaker recent earnings, Organon continues to generate substantial gross and operating margins, indicating that its products retain meaningful economic value. Positive free cash flow also shows the business remains cash-generative, providing a base from which margins and investment capacity could recover.
Bears Say
Sharp Revenue Decline
A revenue decline of this magnitude weakens the company’s earnings base and reduces operating leverage across its commercial platform. If the contraction persists, Organon may have less capacity to fund new products, offset mature-brand erosion, and support debt reduction through internally generated resources.
Compressed Profitability
The steep reduction in net margin shows that recent revenue weakness has translated into substantially lower earnings power. Persistently thin profitability would make results more sensitive to pricing, product mix, and operating costs, while limiting the cash available for reinvestment and balance-sheet improvement.
High Leverage And Limited Flexibility
Very high debt relative to a thin equity base leaves Organon more exposed to operating setbacks and refinancing conditions. This leverage can constrain capital allocation, require a larger share of future cash flow for debt service, and reduce flexibility to invest while the business is under pressure.
1OGN FAQ
What was Organon’s price range in the past 12 months?
What is Organon’s market cap?
When is Organon’s upcoming earnings report date?
How were Organon’s earnings last quarter?
Is Organon overvalued?
Does Organon pay dividends?
What is Organon’s EPS estimate?
How many shares outstanding does Organon have?
What happened to Organon’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Organon?
What is the TipRanks Smart Score and how is it calculated?
Organon Stock Smart Score
Company Description
Organon
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joseph T. Morrissey Jr.
- Employees
- 10,000
- Website
- www.organon.com
- Address
- 30 Hudson Street, Jersey City, NJ, 07302, US
Organon (1OGN) Earnings & Revenues
1OGN Earnings Call
Earnings Call SentimentNeutral
The call presents a mixed picture: several strong, tangible positives (stable full-year guidance, robust biosimilars growth—Hadlima +61% ex-FX—Vtama/Emgality momentum, >$200M cost savings, $960M free cash flow, $390M Jada divestiture and active deleveraging). Offsetting these are meaningful near-term commercial and margin headwinds (revenue down ~3% FY, Q4 -8% CC; Nexplanon channel and policy impacts with Q4 Nexplanon -20% ex-FX; respiratory pricing pressure; gross margin deterioration and a Q4 goodwill impairment), plus some governance/uncertainty from unresolved audit matters. Management expects flat 2026 results and continued focus on cost discipline and balance sheet repair, but several execution and market risks remain.
View all IT:1OGN earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 4 | 2 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 12 | 0 | 0 |